81 results
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
16 May 24
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
10:56am
endpoints and safety data to determine whether the efficacy data for the risk-benefit profile warrants modification or discontinuation of the study
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
12 Apr 24
Regulation FD Disclosure
6:37pm
with a good safety profile (no off - target toxicities) DURABLE COMPLETE RESPONSE (CR) - One subject remains cancer - free ~17 years following treatment 1 … (DCR); Safety of the Current Dose and Schedule Pharmacokinetics (PK) Topline Data Expected first half of 2025
NASDAQ: CNSP PATH TOWARDS POTENTIAL FDA
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the study without modification, which we believe is a monumental step towards … interim futility analysis of efficacy and safety in the Company’s ongoing global, potentially pivotal trial of Berubicin for the treatment of GBM
8-K
EX-10.1
796s41 kddfe7
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
424B4
kuz p37z4py
31 Jan 24
Prospectus supplement with pricing info
4:27pm
8-K
rpecck37kt7gjf6qh
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
EX-99.1
rewi3hvluw76n3hs
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
424B3
uejhum72
30 Nov 23
Prospectus supplement
5:20pm
8-K
EX-99.1
yefcugm57g2ruz
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
EX-99.1
ysne ujif
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am